Close

Seattle Genetics' (SGEN) ADCETRIS sBLA Receives FDA Priority Review

April 20, 2015 9:06 AM EDT Send to a Friend
Seattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login